Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,109,326
  • Shares Outstanding, K 56,401
  • Annual Sales, $ 7,940 K
  • Annual Income, $ -478,570 K
  • 60-Month Beta 0.80
  • Price/Sales 1,130.72
  • Price/Cash Flow N/A
  • Price/Book 10.87
Trade ASND with:

Options Overview

Details
  • Implied Volatility 47.74%
  • Historical Volatility 77.73%
  • IV Percentile 29%
  • IV Rank 29.54%
  • IV High 77.66% on 06/09/21
  • IV Low 35.20% on 11/06/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 31
  • Volume Avg (30-Day) 308
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 20
  • Open Int (30-Day) 1,182

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -2.65
  • Number of Estimates 7
  • High Estimate -1.93
  • Low Estimate -3.09
  • Prior Year -2.70
  • Growth Rate Est. (year over year) +1.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
119.57 +34.27%
on 08/24/21
178.71 -10.16%
on 09/03/21
+40.10 (+33.29%)
since 08/20/21
3-Month
109.36 +46.81%
on 07/27/21
178.71 -10.16%
on 09/03/21
+19.60 (+13.91%)
since 06/18/21
52-Week
109.36 +46.81%
on 07/27/21
183.98 -12.74%
on 12/14/20
+13.55 (+9.22%)
since 09/18/20

Most Recent Stories

More News
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

PFE : 44.48 (+1.34%)
MRK : 72.23 (+0.77%)
LLY : 230.82 (+0.31%)
ASND : 160.21 (-0.80%)
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to potentially create new treatments that make a meaningful difference in patients'...

JPM : 152.88 (-3.04%)
MS : 97.61 (-4.07%)
ASND : 160.21 (-0.80%)
Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa

Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.

PFE : 44.48 (+1.34%)
NVO : 100.00 (-1.39%)
ASND : 160.21 (-0.80%)
IMAB : 72.51 (-4.40%)
Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

- Announced U.S. Food and Drug Administration Approval of SKYTROFA (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency -

ASND : 160.21 (-0.80%)
Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA(R) (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

- SKYTROFA, the first FDA approved treatment utilizing TransCon(TM) technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies -

ASND : 160.21 (-0.80%)
Is a Surprise Coming for Ascendis Pharma (ASND) This Earnings Season?

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ASND : 160.21 (-0.80%)
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to create product candidates that address unmet medical needs, today announced that...

ASND : 160.21 (-0.80%)
Ascendis Pharma A/S Announces Upcoming Investor Presentations in August

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to create new product candidates that address unmet medical needs, today announced...

ASND : 160.21 (-0.80%)
Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon(TM) PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update

- Ascendis expects to complete enrollment of subjects still in screening within one week -

ASND : 160.21 (-0.80%)
Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension

Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.

PFE : 44.48 (+1.34%)
NVO : 100.00 (-1.39%)
ASND : 160.21 (-0.80%)
IMAB : 72.51 (-4.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 168.76
2nd Resistance Point 165.98
1st Resistance Point 163.75
Last Price 160.21
1st Support Level 158.74
2nd Support Level 155.96
3rd Support Level 153.73

See More

52-Week High 183.98
Last Price 160.21
Fibonacci 61.8% 155.48
Fibonacci 50% 146.67
Fibonacci 38.2% 137.86
52-Week Low 109.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar